Results 151 to 160 of about 14,549 (184)
Some of the next articles are maybe not open access.
Management of ANCA associated vasculitis
BMJ, 2020ABSTRACTAnti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a small to medium vessel vasculitis associated with excess morbidity and mortality. This review explores how management of AAV has evolved over the past two decades with pivotal randomized controlled trials shaping the management of induction and maintenance of remission.
Zachary S, Wallace, Eli M, Miloslavsky
openaire +2 more sources
Rituximab in ANCA-Associated Vasculitis
Current Rheumatology Reports, 2017The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV).A PubMed search was carried out to track down articles published between February 2006 and February 2016.
Romina I, Hassan, Angelo L, Gaffo
openaire +2 more sources
Pathogenesis of ANCA-Associated Vasculitis
Current Rheumatology Reports, 2012Antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAV) are a group of systemic vasculitis syndromes characterized by inflammation and necrosis of blood vessel walls. Genetic, epigenetic, and environmental factors contribute to the etiology and pathogenesis of AAV.
Rodrigo, Cartin-Ceba +2 more
openaire +2 more sources
Pathophysiology of ANCA-associated Vasculitis
Advances in Anatomic Pathology, 2017Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is characterized as inflammation of small-sized to medium-sized blood vessels and encompasses several clinicopathologic entities including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited ANCA-associated ...
Turki, Al-Hussain +4 more
openaire +2 more sources
Classification of ANCA-Associated Vasculitis
Current Rheumatology Reports, 2013Classification of the ANCA-associated vasculitides remains controversial. Existing systems, developed by the American College of Rheumatology (ACR) in 1990, the Chapel Hill Consensus Conference (CHCC) in 1994 and updated in 2012, and the European Medicines Agency algorithm, all have deficiencies, especially when applied to unselected patients.
Irfan, Khan, Richard A, Watts
openaire +2 more sources
2013
INTRODUZIONE. Le vasculiti associate agli anticorpi contro proteine dei granuli citoplasmatici dei neutrofili (ANCA) fanno parte delle cosiddette vasculiti sistemiche, un gruppo di condizioni morbose caratterizzate dalla presenza di flogosi e necrosi della parete vascolare e da una marcata eterogeneità dal punto di vista eziopatogenetico, clinico e ...
FERRI, Clodoveo +2 more
openaire +3 more sources
INTRODUZIONE. Le vasculiti associate agli anticorpi contro proteine dei granuli citoplasmatici dei neutrofili (ANCA) fanno parte delle cosiddette vasculiti sistemiche, un gruppo di condizioni morbose caratterizzate dalla presenza di flogosi e necrosi della parete vascolare e da una marcata eterogeneità dal punto di vista eziopatogenetico, clinico e ...
FERRI, Clodoveo +2 more
openaire +3 more sources
Treatment of ANCA-Associated Vasculitis
New England Journal of Medicine, 2003Vasculitis is defined by inflammation of the blood-vessel wall and forms the pathological foundation of a diverse group of individual disease entities. Among the primary systemic vasculitic diseases, Wegener's granulomatosis and microscopic polyangiitis share several common features, including pulmonary capillaritis, pauci-immune focal crescentic ...
openaire +2 more sources
Autoantibodies in ANCA-associated Vasculitis
Rheumatic Disease Clinics of North America, 2010Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides are systemic or more limited conditions characterized by necrotizing destruction of small and medium-sized vessels (eg, capillaries, venules, and arterioles). ANCAs are the most predominant autoantibodies in patients affected by vasculitis, but other autoantibodies may also occur ...
openaire +2 more sources